NCT01677351

Brief Summary

Clonidine, an agonist for alfa2 pre-synaptic, has been shown to be an effective adjuvant therapy for acute postoperative pain and has been shown an effect in sedative, intra-ocular and blood pressure and arrhythmias.The objective of this study is evaluating the analgesic effect of clonidine and its repercussion on arterial and intraocular pressure and arrhythmias for cataract surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_2 pain

Timeline
Completed

Started Jul 2011

Typical duration for phase_2 pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

August 1, 2012

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 3, 2012

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

September 3, 2012

Status Verified

August 1, 2012

Enrollment Period

1.2 years

First QC Date

August 1, 2012

Last Update Submit

August 31, 2012

Conditions

Keywords

clonidinecataract surgeryarrythmiaanesthesic medication

Outcome Measures

Primary Outcomes (1)

  • intensity of pain

    Pain intensity will be assessed by numeric rating scale.

    30 minutes before surgery, during the surgery

Secondary Outcomes (1)

  • intraocular pressure

    30 minutes and during the surgery

Other Outcomes (2)

  • antiarrythmic effect

    30 minutes before surgery and during the surgery

  • blood pressure

    30 minutes before and during the surgery

Study Arms (2)

group 2: clonidine 4mcg.kg

ACTIVE COMPARATOR

this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.

Drug: Clonidine

Group 1: sterile saline solution

PLACEBO COMPARATOR

this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery

Drug: placebo

Interventions

4 mcg.kg-1, 20 minutes before cataract surgery

Also known as: cataract surgery, anesthesic drugs
group 2: clonidine 4mcg.kg
Group 1: sterile saline solution

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • cataract surgery
  • topical anesthesia

You may not qualify if:

  • myocardial ischemia
  • psychiatric disease
  • chronic pain
  • drugs dependency
  • use of beta-blockage channel drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Federal University of Sao Paulo

São Paulo, São Paulo, Brazil

RECRUITING

Related Publications (1)

  • Santiago AE, Issy AM, Sakata RK. Effects of preoperative intravenous clonidine in patients undergoing cataract surgery: a double-blind, randomized trial. J Ophthalmol. 2014;2014:346549. doi: 10.1155/2014/346549. Epub 2014 Sep 2.

MeSH Terms

Conditions

PainArrhythmias, Cardiac

Interventions

ClonidineCataract Extraction

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular DiseasesPathologic Processes

Intervention Hierarchy (Ancestors)

ImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsRefractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Rioko K Sakata, Study Chair

    Federal University of São Paulo

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
medical resident, principal investigator

Study Record Dates

First Submitted

August 1, 2012

First Posted

September 3, 2012

Study Start

July 1, 2011

Primary Completion

September 1, 2012

Study Completion

December 1, 2012

Last Updated

September 3, 2012

Record last verified: 2012-08

Locations